McKinsey and Co

Activities: Media

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Logistics

Shaping the pharmaceutical industry in Africa

Africa highlighted as a market with great potential for life science and healthcare companies
Finance

Green Cross expands cell therapy business in China

Company to build a cell therapy facility in the southwestern Chinese province to produce and distribute cell therapy products in China
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
You need to be a subscriber to read this article.
Click here to find out more.
Media

Precision drugs: seeking clarity through the haze

The dawn of personalised medicine has arrived, but now that it is here its implementation is not as clear cut as previously envisaged. Susan Birks reports on some future challenges
Regulatory

Measure to boost clinical trials in India backfires

Some US and Canadian companies stop clinical trials in India following an amendment to the rules that they say could lead to ‘unreasonable claims’ by patients
You need to be a subscriber to read this article.
Click here to find out more.

A healthy outlook for targeted medicines

The US leads in the market for biomarkers and theranostics with oncology being the focus, but other disease areas are following rapidly and the personalised medicine market is set to grow at a rapid pace over the next five years
Subscribe now